Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 562 in Relapsed/Refractory B-cell Lymphomas
NCT03571828Phase 1Terminated
- Sponsor
- Amgen
- Start
- Oct 2018
- Primary completion
- Jan 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of AMG 562 in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL) (2 arms), sponsored by Amgen. Primary endpoints: Number of Participants Who Experienced a Dose Limiting Toxicity and Number of Participants Who Experienced a Treatment-emergent Adverse Event up to 2 years. Started Oct 2018; status: terminated.
02
Drugs
AMG 562
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03571828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571828.